MKI67 and neoplasm: The variable prognostic factors include tumor size, lymph node status, grade, histological type, and molecular features, such as expression of ER/PgR, HER2, and proliferation markers (e.g., Ki-67), which are used to divide BCs into the molecular-specific subtypes with different diagnostic and therapeutic pathway, risk of recurrence and response to treatment [1,2].